Evren Technologies, Inc offering is now closed and is no longer accepting investments.

INVEST IN EVREN TECHNOLOGIES, INC TODAY!

Advancing PTSD Treatment with an FDA Breakthrough Device

Evren Technologies is developing a discrete earbud that utilizes a groundbreaking treatment for PTSD to help people easily manage their symptoms and improve outcomes. Backed by clinical evidence, the Phoenix® improves patient health and well-being with fewer side effects and higher patient engagement than seen with current prescription drugs and therapies.*

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Evren Technologies, Inc

$250,650.17 Raised

REASONS TO INVEST

Reasons Icon

Large market: $20B+ market opportunity addressing 15M Americans.

Reasons Icon

Experienced Leadership: Management team with a proven track record, including 9 successful exits, $150M+ raised, and 6 FDA-cleared devices.

Reasons Icon

Validated Technology: FDA Breakthrough Device Designation, nearly $500K in non-dilutive funding from the Department of Defense and National Institute of Mental Health.

Evren Technologies currently has a working prototype of the Phoenix® earbud and a beta version of the accompanying app

*Information based on internal research with resources provided by the National Center for PTSD (  source)

A Groundbreaking Treatment for PTSD

Millions are suffering from PTSD each year, but current treatments simply aren’t enough, leaving 66% of patients seeking better treatment options.



This is why we’re creating the Phoenix®, a non-invasive, affordable, and drug-free treatment for PTSD. The Phoenix is an innovative earbud device that will deliver personalized vagal nerve stimulation (VNS) to reduce PTSD severity and improve quality of life without the harmful side effects of prescription drugs. The pilot trial results were exceptional, earning the Phoenix Breakthrough Device Designation from the FDA. More importantly, PTSD patients loved the device. 100% of pilot trial participants wanted to keep their device after the trial, even those who achieved remission.


The device reduces PTSD severity, which includes symptoms such as  depression, anxiety, insomnia, nightmares & flashbacks, social avoidance, and suicidality — and does so with no significant side effects. The Phoenix was recently awarded Breakthrough Device Designation by the FDA based on early clinical data, and we’re now ready to launch it into the next phase of development as we look to serve those chronically suffering from PTSD. 

The Problem


Current Treatments Aren’t Enough

Despite millions of Americans dealing with PTSD on a daily basis, far too many patients are still looking for relief. 15M Americans are impacted by PTSD in a typical year, and the pandemic has been far from typical, with rates soaring as high as 60M.


(source)


Despite millions of Americans dealing with PTSD on a daily basis, far too many patients are still looking for relief. The primary treatment option is antidepressants, which can cause increased suicidality and are intended only for short-term use. 


Therapy, another common treatment in the patient roadmap, is more time and resource-intensive than many people can afford, and still lacks proper research, phenotyping, and individualization—oftentimes worsening symptoms. Researchers and academics agree that current therapies are inadequate, indicating a pressing need for new approaches to the issue.

The Solution


A Better Way to Treat PTSD

*The above rendering is a computer generated simulation.


The Phoenix will treat PTSD by stimulating the vagus nerve with a light electrical tingle, providing personalized dosing based on stress levels. It is completely non-invasive and has no significant adverse side effects. It's portable and discrete, allowing for treatment anywhere you need it. In short, it will empower users to take back control of their lives.


The result? PTSD patients love the Phoenix! 100% of users wanted to keep using the Phoenix after the pilot study and all of them were willing to pay out-of-pocket for it. Here is what they had to say:



*These testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.

The Market


$22.5B Addressable Market Opportunity

PTSD is an enormous global market, valued at $22.5B in the US alone.* The Phoenix is an extremely scalable technology at the forefront of 2 of the fastest growing medical device markets: Bioelectronic Medicine and Wearable Medical Devices.

*Information based on internal research done by Evren Technologies



Our Traction


FDA designation, NIMH and DoD funding, and an Elite Team

Since Evren started in 2019, we’ve made great strides and have seen a phenomenal response from both PTSD patients and governing agencies. 


  • FDA Breakthrough Device Designation
  • $256,000 in funding from the National Institute of Mental Health
  • $222,000 in funding from the Department of Defense

This traction has allowed Evren to assemble an elite team of leading experts in PTSD, VNS, and military healthcare.




In the Press

Why Invest


Working towards a better future for those suffering from PTSD

We envision a better future for those suffering from PTSD—though it doesn’t stop there. The Phoenix is an extremely scalable technology, with vagal nerve stimulation approved for the treatment of many other disorders, including epilepsy, opioid withdrawal, major depressive disorder, and migraines, with potential application for a longer list that includes anxiety, insomnia, long COVID and traumatic brain injury. 


Join us on our mission to improve countless lives, enable a happier, healthier future, and empower patients to #RiseAbovePTSD.


*The above is a rendering of Evren's Phoenix earbud. Images feature a computer generated model. Product is still currently under development.

ABOUT

HEADQUARTERS

404 SW 140th Terrace, Suite 50
Gainesville, FL 32669
VALUATION

$15.09M

Evren Technologies is developing a discrete earbud that utilizes a groundbreaking treatment for PTSD to help people easily manage their symptoms and improve outcomes. Backed by clinical evidence, the Phoenix® improves patient health and well-being with fewer side effects and higher patient engagement than seen with current prescription drugs and therapies.*

TEAM

Weaver Gaines
Weaver Gaines
Chairman & CEO

Weaver Gaines has over 40 years of entrepreneurial, management, and legal experience, including over 25 years as a founder, fund-raiser, and manager of start-up life science companies. Most recently, he was a co-founder and CEO of OBMedical Company, a medical device company that developed and received FDA clearance for an electronic maternal fetal monitor, which was acquired by Philips Healthcare in 2018.

Gaines received a BA from Dartmouth College and a JD from the University of Virginia School of Law and was an Infantry officer who served in Vietnam from 1969-70, with a final rank of Captain.

Neil Euliano

Neil Euliano

Chief Technology Officer

Neil Euliano has spent the past 20 years leading teams developing medical devices and technology. He is the chief designer and manager of the FDA cleared Philips Healthcare VentAssist team that developed intelligent decision support software for ventilated patients. He holds over 40 US patents and has ten more pending. In addition, he has a long history in managing multi-disciplinary medical development teams and 19 years of experience managing R&D grants, including over $12M in industry and government funded research. His commercialization and entrepreneurial experience includes being the cofounder of two companies, both of which led to FDA clearance, commercial sales, and acquisition. He has been involved in the successful FDA clearance of more than 6 medical devices. 

Euliano holds a PhD in Signal Processing and Electrical Engineering, an MSEE in Electrical Engineering, and a BSE in Computer Science all from the University of Florida.

Joshua Kelly

Joshua Kelly

Associate Product Manager and Corporate Secretary

Josh Kelly started with the Company as an Associate Product Manager, but was appointed Corporate Secretary in December 2021. He previously was a consultant with Asymetric Solutions, and a Deptuy State Director - Wisconsin for In Field Strategies. He gratudated with a degree in public relations from the University of Florida.

Kimberly A Ramsey

Kimberly A Ramsey

Chief Financial Officer

A serial entrepreneur, with 30 years progressive corporate finance and operations experience Ramsey has played a key role in raising over $100 million, including several successful IPO’s. Most recently, she has been providing executive consulting services to medical device start-ups as founder and president of Bio/Med CXO. As co-founder and Chief Financial Officer for OBMedical Company, she played a key role in forwarding a ground-breaking wireless fetal/maternal monitor for use in labor and delivery departments, raising over $10M in private equity, leading to a successful acquisition by Philips Healthcare. Prior to that, she was key to successful mergers and IPOs in the biotech, med device and high-tech arenas. Ramsey holds a BSAc from the Fisher School of Accounting at the University of Florida. 

Stephanie Warrington

Stephanie Warrington

Member of the board of directors

Ms. Warrington has been an independent consultant since 2014, advising a wide range of early stage medtech and bgiotech companies. She was a founder, president and director of TrueMotion Spine, Inc., a Co-founder and VP, Corporate Development for Xhale, Inc., and President of Synogen, Inc. She holds an MBA, an MHA, and a BS in Business Administration from the University of Florida.

Robert V. House

Robert V. House

Member of Board of Directors

Dr. House is an independent consultant and was previously Senior Vice President, Government Contracts of Ology Bioservices, with over 20 years' experience leading the contract management and oversight process of major US Government contracts with various agencies including the DoD, NIH, HHS, and other federal entities. He is also a director of Arrevus, Inc. He has more than 76 peer reviewed publications, plus numerous review articles, book chapters, and books. In addition, he is an adjunct professor at George Mason University. Dr. House is a graduate of the University of North Carolina at Chapel Hill, where he received his BA (Zoology), his MS in Public Health, and his PhD (Medical Parasitology). He will play a major role in our non-dilutive financing initiative. 

Richard Ferrari

Richard Ferrari

Member of Board of Directors

Mr. Ferrari is a Co-Founder of De Novo Ventures which has $650 million under management and which is one of the premier firms dedicated to Medical Devices and Biotechnology. He has raised over a billion dollars for companies he has directly influenced and participated in approximately a 1.5 billion dollars in acquisition events. 

Additionally, he has been a successful CEO of two publicly traded medical technology companies. Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters which was eventually acquired for $125 million by Boston Scientific. His most recent success, CardioThoracic Systems (CTS), the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, was acquired by Guidant for $350 million in November 1999. Mr. Ferrari was a co-founder of CTS and the force that led the company to an initial public offering in only 7 months, the fastest of any medical technology company in history. Additionally, Rich was the co-founder of the MTG Group which developed Ensure femoral closure device which sold to J&J for $100 Mill returning 10x to investors and also IVS which developed the Star Close and sold to Abbott for $100Mill also returning 10x to investors. He is also the co-founder of Transaortic an integrated femoral sheath and embolic capture system for TAVR procedure which sold last year to Medtronic. He was also the Executive Chairman of SentreHeart where he led the acquisition to Atricure for $300Mill. 

Mr. Ferrari is the recipient of the Mallinckrodt Award for Excellence in Medicine and has been a finalist for the Entrepreneur of the Year Award. He holds a BS degree from Ashland University and an MBA from the University of South Florida.

Suha Jhaveri

Suha Jhaveri

Member of the Board of Directors

Ms. Jhaveri is presently the Chief Commercial Officer and Head of Business Development of Leyden Labs. Previously she was VP, Market Development of Vir Biotechnology, Global Commercial Leader and New Product Planning for Ultragenyx Pharmaceuticals. Prior to that, she was the Chief Operating Officer of OBMedical Company, and held a variety of executive positions with biotech and tech companies as well as working as a consultant for Boston Consulting Group. She holds an MBA from Harvard, a MA in Economic Development from the University of Sussex, and a BA in International Relations from Stanford University.

Marcus Elliot

Marcus Elliot

VP of R&D

Vice President of R&D. Responsible for executing on the Company's overall technology vision & strategy, driving development execution, and bringing products to market on time and within budget.

TERMS

Evren Technologies, Inc
Overview
PRICE PER SHARE
$6.65
DEADLINE
Aug 30, 2022
VALUATION
$15.09M
AMOUNT RAISED
$250,650.17
Breakdown
MIN INVESTMENT
$399.00
MAX INVESTMENT
$1,069,985.00
MIN NUMBER OF SHARES OFFERED
1,503
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
160,900

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

Evren Technologies, Inc

Corporate Address

:

404 SW 140th Terrace, Suite 50, Gainesville, FL 32669

Offering Minimum

:

$9,994.95

Offering Maximum

:

$1,069,998.30

Minimum Investment Amount

(per investor)

:

$399.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

1,503

Maximum Number of Shares Offered

:

160,902

Price per Share

:

$6.65

Pre-Money Valuation

:

$15,085,870.80











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*

Time-Based

Friends and Family Early Birds

Invest within the first 72 hours and receive 15% bonus shares.

Early Bird Bonus

Invest within the first week (7 calendar days) and receive 10% bonus shares.

Amount-Based

Investor | $1,000+

Invest $1,000+ and receive 50% off device purchase (coupon for use once the product is available on the market).

Watt | $5,000+

Invest $5,000+ and receive 5% bonus shares + 50% off device purchase (coupon for use once the product is available on the market).

Franklin | $10,000+

Invest $10,000+ and receive 10% bonus shares + 50% off 2 device purchases (coupons for use once the product is available on the market).

Edison | $25,000+

Invest $25,000+ and receive 20% bonus shares + 50% off 3 device purchases (coupons for use once the product is available on the market).

Tesla | $50,000+

Invest $50,000+ and receive 25% bonus shares + 50% off 4 device purchases (coupons for use once the product is available on the market).

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Evren Technologies, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $6.65 / share, you will receive 110 shares Common Stock, meaning you'll own 110 shares for $665. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Insider Investment Notice

Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.

ALL UPDATES

08.28.22

This is Your Last Chance!

This is your last chance to invest in a solid company developing the revolutionary Phoenix - a wearable earbud device designed to treat persistent symptoms of PTSD. .  


Evren Technologies is bringing PTSD treatment to the next level with our innovative Phoenix earbud, a revolutionary vagus nerve stimulation therapy designed to effectively alleviate symptoms of PTSD. 100% of trial participants wanted to keep the device after the trial ended! 


PTSD is currently a $22.5 Billion-dollar market, yet 66% of those suffering are still seeking new treatments in hopes of finding something that finally works. 15 Million Americans suffer from PTSD in any given year, and an estimated 60 million had PTSD during the height of the COVID shutdown.


The Phoenix was recently awarded Breakthrough Device Designation by the FDA, demonstrating that it could provide better treatment than the current standard of care in the serious, life-threatening condition of PTSD. 


Evren Technologies is determined to improve the lives of soldiers afflicted with Acute Stress Reactions. In April of 2022, Evren Technologies was recently awarded a $172K contract from the military to further support soldier safety and performance. 


Evren also received an SBIR from the National Institute of Mental Health as well as a contract from the Army Medical Research and Development Command.


We envision a better future for people suffering from PTSD, and with the growing support of investors like you, we can make this dream a reality.


Benefits of early investing include:


  • $1,000+ Investment - 50% off device

  • $5,000+ Investment - 5% Bonus Shares + 50% off device

  • $10,000+ Investment - 10% Bonus Shares + 50% off 2 devices

  • $25,000+ Investment - 20% Bonus Shares + 50% off 3 devices

  • $50,000+ Investment - 25% Bonus Shares + 50% off 4 devices


Now is the time to join our mission to create a brighter future for those struggling with debilitating symptoms. Together, we can help ease suffering and help people rise above PTSD! 


Please help spread the word by sharing with your friends, family, and network!



Warmly,
Weaver Gaines
CEO
Evren Technologies

08.26.22

Why Miss Out on a Great Opportunity?

Time is running out to invest in a solid company developing the revolutionary Phoenix earbud - an all in one system designed to alleviate the symptoms of PTSD. .  


Join our growing investor community as we take PTSD treatment to the next level. Evren’s innovative Phoenix earbud uses revolutionary vagus nerve stimulation therapy to decrease symptoms of PTSD. 100% of early trial participants wanted to keep the device after the trial ended! 


PTSD is a $22.5 Billion-dollar market yet 66% of those suffering are still trying to find relief from symptoms. 15 Million Americans suffer from PTSD in any given year and many are currently unable to fully recover. 


Now is the time to join our mission to create a brighter future for those struggling with debilitating symptoms. Together, we can help ease suffering and help people rise above PTSD! 


Benefits of early investing:


  • $1,000+ Investment - 50% off device

  • $5,000+ Investment - 5% Bonus Shares + 50% off device

  • $10,000+ Investment - 10% Bonus Shares + 50% off 2 devices

  • $25,000+ Investment - 20% Bonus Shares + 50% off 3 devices

  • $50,000+ Investment - 25% Bonus Shares + 50% off 4 devices


We envision a better future for people suffering from PTSD, and with the growing support of investors like you, we can make this dream a reality.


Please share this promising investment opportunity with your friends, family, and network! 



Warmly,
Weaver Gaines
CEO
Evren Technologies

08.24.22

Only 5 Days Left to Invest!


Time is running out to invest in our StartEngine campaign. There are only 5 days left to get in on the ground floor of the revolutionary Phoenix earbud - an all in one system designed to alleviate the symptoms of PTSD


An astounding 100% of trial participants wanted to keep the device! 


Perks of becoming an early investor include:


  • $5,000+ Investment: 5% bonus shares + 50% off device

  • $10,000+ Investment: 10% bonus shares + 50% off 2 devices

  • $25,000+ Investment: 20% bonus shares + 50% off 3 devices

  • $50,000+ Investment: 25% bonus shares + 50% off 4 devices


We envision a better future for people suffering from PTSD and with the growing support of investors like you, we can make this dream a reality.


Learn more about joining our investor community by visiting our raise page today. Please help spread the word by sharing with your friends, family, and network! 


Warmly,
Weaver Gaines

08.22.22

Time is Running Out on Evren’s Campaign!


Time is running out to invest in Evren’s campaign on StartEngine. Secure your spot as a member of Evren’s community to take advantage of the early investor perks. 


Join Evren Technologies as we take PTSD treatment to the next level with our innovative Phoenix earbud, which uses revolutionary vagus nerve stimulation therapy to decrease symptoms of PTSD. 100% of trial participants wanted to keep the device after the trial ended! 


The Phoenix was recently awarded Breakthrough Device Designation by the FDA, demonstrating that it could provide better treatment than the current standard of care in the serious, life-threatening condition of PTSD. 


Evren is also the recipient of a SBIR from the National Institute of Mental Health and a contract from the Army Medical Research and Development Command.


In April of 2022, Evren Technologies was awarded a $172K contract from the military in order to support soldier safety and performance. 


Now is the time to join our mission to create a brighter future for those struggling with debilitating symptoms. Together, we can help ease suffering and help people rise above PTSD! 


Warmly,
Weaver Gaines
CEO
Evren Technologies

08.17.22

Need Another Reason to Invest? Ask Thomas!

Read this moving testimonial from one of our recent investors detailing why he decided to support Evren Technologies’s mission. 


"I invested in Evren Technologies because I have suffered from Major Depressive Disorder for almost 23 years. I know there is a huge unmet need for better PTSD, depression, and anxiety treatments. 


The technology that Evren has developed and manufactured is groundbreaking and exciting. First, to know that so many people could receive such a simple but effective treatment is encouraging, especially without needing health insurance. Secondly, the type of device that Evren has developed is convenient and side-effect free.


The unmet need for better PTSD treatment is huge. So many of our country’s military men and women are being affected mentally. After sacrificing their lives, families, and time, they deserve the best treatment options available.


With the onset of the pandemic in 2020, and the fallout that has occurred, mental illness is reaching all time high levels. More treatments like The Phoenix device need to be made readily available to ALL that need it, regardless of financial or health insurance status.


As someone who suffers from mental illness, I think it’s wonderful what Evren Technologies has developed for those suffering from PTSD. I would love to see Evren Technologies take treatment to a new level. I would also like to see Evren’s device indications expand, to treat depression, anxiety, personality disorders, schizophrenia, and all types of mental illness.


To me, it’s a privilege and pleasure, to be able to aid in furthering Evren Technologies’s research and development." - Thomas Warrington


Pilot study participants saw an average 18.4 pt reduction in CAPS-5. No wonder 100% of our participants wanted to keep The Phoenix earbud!  


Visit our raise page on StartEngine to learn more about our mission to enable a happier, healthier future for people with PTSD. 



Warmly,
Weaver Gaines
CEO
Evren Technologies


“This testimonial may not be representative of the experience of other customers and is not a guarantee of future performance or success.”

08.15.22

Don’t Miss Evren’s Farewell Webinar!


Are you on the fence about potentially investing or considering reinvesting in Evren Technologies? Tomorrow is your last chance to speak to CEO Weaver Gaines about exciting developments in Evren’s future. 


Don’t miss our live Q&A investor webinar on August 16th at 4:00 pm EDT! There is only 1 day left to register! 


PTSD is an underserved $22.5B market which leaves 66% of patients still seeking relief through new treatment solutions. Evren Technologies was recently awarded a Breakthrough Device Designation by the FDA for demonstrating the Phoenix can better alleviate symptoms than current available therapies with no side effects


15 million adults in the U.S. suffer from PTSD every year, and by investing in Evren Technologies, you can contribute to making a real difference in their lives. 


Sign up today for one final, farewell webinar with the Evren Team before our campaign closes. 


Remember to share our raise page with your network so they can learn more about investment opportunities!



Warmly,
Weaver Gaines
CEO
Evren Technologies

08.15.22

Only 2 Weeks Left to Invest in Evren!


Time is becoming increasingly limited to invest in our StartEngine campaign. 


There are only 2 weeks left to get in on the ground floor of the company developing the revolutionary Phoenix earbud - an all in one system designed to alleviate the symptoms of PTSD. .  


PTSD is an underserved, $22.5 Billion-dollar market with 66% of those suffering currently seeking new treatment solutions. 15 Million Americans will suffer from PTSD in any given year, and over 60 million had PTSD during the height of the COVID shutdown.


Now is the time to invest in a revolutionary treatment designed to combat PTSD symptoms - with no side effects. 100% of trial participants wanted to keep the device!


We envision a better future for people suffering from PTSD, and with the growing support of investors like you, we can make this dream a reality.


Learn more about joining our investor community by visiting our raise page today. Please help spread the word by sharing with your friends, family, and network! 



Warmly,
Weaver Gaines
CEO
Evren Technologies

08.13.22

Last Webinar Only 3 Days Away!

Hello Evren Community!


Don’t miss your last chance to chat with Evren’s CEO, Weaver Gaines! He is hosting a final investor Q&A webinar before our StartEngine campaign ends. 


There are only 3 days left to register!


Reserve your spot today to chat with the Evren team on August 16th at 4:00pm EDT.


With the continuous support of our growing inverter community, Evren Technologies is primed to take on the next stages of research and development for our revolutionary technologies. 


Evren’s Phoenix earbud has been shown to alleviate symptoms of PTSD without adverse side effects, greatly improving patients’ quality of life. 


Together with investors like you, we are helping people rise above PTSD by alleviating debilitating symptoms. 


Please share this amazing opportunity with your friends, family, and network. 



Warmly,
Weaver Gaines
CEO
Evren Technologies

08.13.22

Heal From Trauma With The Phoenix by Evren Technologies!

Millions of Americans suffer from the debilitating symptoms that come from surviving trauma. PTSD affects everyone differently, but many experience extreme anxiety, depression, anger, social isolation, insomnia, and suicidality. Symptoms can interfere with someone’s interpersonal relationships and even prevent them from being able to work. Living with panic and flashbacks can leave a person too exhausted to conduct their daily lives. 


Unfortunately, most of the current treatments available don’t do enough to eliminate symptoms of PTSD. Over 66% of patients who begin therapy are still seeking relief from their most persistent symptoms. 


In our clinical trials, an astounding 100% of participants experienced reduced symptoms and wanted to keep the device! Overall, participants experienced up to a 91% decrease in symptoms. 


Recently, the Phoenix was awarded a Breakthrough Device Designation by the FDA, which will help us fast track our trials. Evren Technologies is dedicated to helping alleviate symptoms of PTSD for millions of people. We continue to further research in this developing field and develop new technologies to help people rise above PTSD. 


PTSD treatment is a $22.5B market that continues to grow every year. You can help us provide relief to those who need it most by investing in Evren Technologies for as little as $399. 


With the help of our growing investor community, we can alleviate the suffering of people with PTSD everywhere. 


Visit our raise page on StartEngine today to learn more about the benefits of investing in Evren Technologies. Please share with your friends, family, and network! 


Warmly,

Weaver Gaines

CEO

Evren Technologies

08.11.22

VNS was Featured in the NY Times!


Check out this recent article on Vagal Nerve Stimulation (VNS) in the New York Times! Read about how this revolutionary technology is changing lives. Evren Technologies was featured in the New York Times in June.

 

Our wellbeing is dependent on a functional and adaptive nervous system. PTSD leads to a maladaptive system, which makes people feel unsafe all the time. The key to regulating the safety response is the vagus nerve, which basically controls the safety response.


The Phoenix delivers stimulation to the auricular branch of the vagus nerve through the ear, bringing it back into balance. This allows PTSD victims to finally feel safe again.


The continued coverage of VNS by major publications is a testament to the rapid growth of the field. This is your chance to get in at the ground floor by investing in Evren, one of the top biotech campaigns on StarEngine!


Join our mission to create a brighter future for those struggling with debilitating symptoms. Visit our raise page on StartEngine to learn about the perks of early investment. Please share this great opportunity with your family, friends, and network.


Together, we can ease suffering and help people rise above PTSD!




Warmly,
Weaver Gaines
CEO
Evren Technologies

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Evren Technologies, Inc.

$399.00

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$399.00

Early Bird Bonus

Invest within the first week (7 calendar days) and receive 10% bonus shares.

$1,000.00

Investor | $1,000+

Invest $1,000+ and receive 50% off device purchase (coupon for use once the product is available on the market).

$5,000.00

Watt | $5,000+

Invest $5,000+ and receive 5% bonus shares + 50% off device purchase (coupon for use once the product is available on the market).

$10,000.00

Franklin | $10,000+

Invest $10,000+ and receive 10% bonus shares + 50% off 2 device purchases (coupons for use once the product is available on the market).

$25,000.00

Edison | $25,000+

Invest $25,000+ and receive 20% bonus shares + 50% off 3 device purchases (coupons for use once the product is available on the market).

$50,000.00

Tesla | $50,000+

Invest $50,000+ and receive 25% bonus shares + 50% off 4 device purchases (coupons for use once the product is available on the market).

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$250,650.17
INVESTORS
116
MIN INVEST
$399.00
VALUATION
$15.09M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.